Methods of treating and diagnosing Parkinsons disease and related dysautonomic disorders
AssigneeCuremark, LLC
InventorJoan M. Fallon
Life of this patent
Estimating the term…
Abstract
A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder.
Claims41
A method of diagnosing a patient comprising:
- a. obtaining a fecal sample from the patient;
- b. determining a level of chymotrypsin present in the fecal sample;
- and
- c. diagnosing the patient as having a likelihood to develop a dysautonomic disorder if the determined fecal chymotrypsin level is 8.4 U/gram or less, wherein said dysautonomic disorder is selected from the group consisting of Familial dysautonomia (FD), Diabetic autonomic failure, Parkinson's disease or Orthostatic intolerance.
A method of screening a patient comprising:
- a. determining the level of chymotrypsin present in a fecal sample obtained from the patient;
- and
- b. identifying the patient as having a likelihood to develop a dysautonomic disorder if the determined chymotrypsin level is 8.4 U/gram or less, wherein said dysautonomic disorder is selected from the group consisting of Familial dysautonomia (FD), Diabetic autonomic failure, Parkinson's disease or Orthostatic intolerance.
A method of confirming a diagnosis of a patient as having a dysautonomic disorder or a likelihood to develop a dysautonomic disorder, comprising:
- a. obtaining a fecal sample from the patient;
- b. determining a level of chymotrypsin present in the fecal sample;
- and
- c. confirming the diagnosis of the patient as having a dysautonomic disorder or a likelihood to develop a dysautonomic disorder if the determined fecal chymotrypsin level is 8.4 U/gram or less, wherein said dysautonomic disorder is selected from the group consisting of Familial dysautonomia (FD), Diabetic autonomic failure, Parkinson's disease or Orthostatic intolerance.
A method of confirming a diagnosis of a patient as having a dysautonomic disorder or a likelihood to develop a dysautonomic disorder comprising:
- a. determining the level of chymotrypsin present in a fecal sample obtained from the patient;
- and
- b. confirming the diagnosis of the patient as having a dysautonomic disorder or a likelihood to develop a dysautonomic disorder if the determined chymotrypsin level is 8.4 U/gram or less, wherein said dysautonomic disorder is selected from the group consisting of Familial dysautonomia (FD), Diabetic autonomic failure, Parkinson's disease or Orthostatic intolerance.
A method of determining if an individual has a likelihood propensity to develop a dysautonomic disorder comprising:
- a. determining the fecal chymotrypsin levels of the patient over a period of time;
- and
- b. determining that the individual has a likelihood to develop a dysautonomic disorder if the determined fecal chymotrypsin levels exhibit a decreasing trend over time and at least one level is 8.4 U/gram or less, wherein said dysautonomic disorder is selected from the group consisting of Familial dysautonomia (FD), Diabetic autonomic failure, Parkinson's disease or Orthostatic intolerance.
A method of diagnosing a patient comprising:
- a. determining a level of chymotrypsin present in a fecal sample obtained from the patient;
- and
- b. diagnosing the patient as having a dysautonomic disorder or having a likelihood to develop a dysautonomic disorder if the determined fecal chymotrypsin level is less than a normal fecal chymotrypsin level, wherein said dysautonomic disorder is selected from the group consisting of Familial dysautonomia (FD), Diabetic autonomic failure, Parkinson's disease or Orthostatic intolerance.
A method of screening a patient comprising:
- a. determining a level of chymotrypsin present in a fecal sample obtained from the patient;
- and
- b. identifying the patient as having a likelihood to develop a dysautonomic disorder if the determined fecal chymotrypsin level is less than a threshold fecal chymotrypsin level, wherein said dysautonomic disorder is selected from the group consisting of Familial dvsautonomia (FD), Diabetic autonomic failure, Parkinson's disease or Orthostatic intolerance.
A method of confirming a diagnosis of a patient as having a dysautonomic disorder or having a likelihood to develop a dysautonomic disorder, comprising:
- a. determining a level of chymotrypsin present in a fecal sample obtained from the patient;
- and
- b. confirming the diagnosis of the patient as having a dysautonomic disorder or having a likelihood to develop a dysautonomic disorder if the determined fecal chymotrypsin level is less than a normal fecal chymotrypsin level, wherein said dysautonomic disorder is selected from the group consisting of Familial dysautonomia (FD), Diabetic autonomic failure, Parkinson's disease or Orthostatic intolerance.
A method of confirming a diagnosis of a patient as having a dysautonomic disorder or having a likelihood to develop a dysautonomic disorder, comprising:
- a. determining a level of chymotrypsin present in a fecal sample obtained from the patient;
- and
- b. confirming the diagnosis of the patient as having a dysautonomic disorder or having a likelihood to develop a dysautonomic disorder if the determined fecal chymotrypsin level is less than a threshold fecal chymotrypsin level, wherein said dysautonomic disorder is selected from the group consisting of Familial dysautonomia (FD), Diabetic autonomic failure, Parkinson's disease or Orthostatic intolerance.
Dependencies are inferred from the claim text.